{"id":67946,"date":"2026-10-23T06:12:54","date_gmt":"2026-10-23T00:42:54","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=67946"},"modified":"2026-10-23T15:25:22","modified_gmt":"2026-10-23T09:55:22","slug":"new-series-of-interactive-cardiology-mcqs-8","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/","title":{"rendered":"New Series of Interactive Cardiology MCQs 8"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<!-- \n  INSTRUCTIONS FOR WORDPRESS:\n  1. Add a new \"Custom HTML\" block in your WordPress editor.\n  2. Copy everything from line 1 to the end of this file.\n  3. Paste it into the Custom HTML block.\n  4. Preview or Publish the post to see the interactive MCQs in action.\n-->\n\n<script src=\"https:\/\/cdn.tailwindcss.com\"><\/script>\n<script>\n  tailwind.config = {\n    corePlugins: {\n      preflight: false, \/\/ Ensures maximum compatibility with WordPress themes\n    }\n  }\n<\/script>\n\n<div class=\"cardio-quiz-wrapper font-sans bg-slate-950 text-slate-200 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-cyan-900\/50\" style=\"box-sizing: border-box; font-family: 'Inter', system-ui, sans-serif;\">\n  \n  <!-- Ambient Dark Medical Theme Glows -->\n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-20 bg-[radial-gradient(ellipse_at_top,_var(--tw-gradient-stops))] from-cyan-600 via-slate-900 to-slate-950\"><\/div>\n  \n  <!-- Header Banner -->\n  <div class=\"relative text-center pb-6 border-b border-cyan-900\/50 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-600 to-teal-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-widest shadow-lg shadow-cyan-900\/50 mb-4\">\n      Advanced Clinical Series\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-400 to-teal-300 m-0 drop-shadow-md\">\n      Cardiology MCQs: Part 8\n    <\/h1>\n    <p class=\"text-sm md:text-base text-slate-400 mt-3 max-w-2xl mx-auto font-medium\">\n      Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials.\n    <\/p>\n  <\/div>\n\n  <!-- Sticky Live Scoreboard -->\n  <div class=\"sticky top-4 z-40 bg-slate-900\/85 backdrop-blur-xl border border-cyan-800\/60 rounded-2xl p-4 md:p-5 mb-8 shadow-xl shadow-cyan-900\/20 flex flex-wrap items-center justify-between gap-4 transition-all\">\n    <div class=\"flex items-center gap-4\">\n      <div class=\"w-12 h-12 rounded-full bg-cyan-950 flex items-center justify-center border border-cyan-700 shadow-inner text-cyan-400\">\n        <svg class=\"w-6 h-6\" fill=\"none\" stroke=\"currentColor\" viewBox=\"0 0 24 24\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\"2\" d=\"M9 12l2 2 4-4M7.835 4.697a3.42 3.42 0 001.946-.806 3.42 3.42 0 014.438 0 3.42 3.42 0 001.946.806 3.42 3.42 0 013.138 3.138 3.42 3.42 0 00.806 1.946 3.42 3.42 0 010 4.438 3.42 3.42 0 00-.806 1.946 3.42 3.42 0 01-3.138 3.138 3.42 3.42 0 00-1.946.806 3.42 3.42 0 01-4.438 0 3.42 3.42 0 00-1.946-.806 3.42 3.42 0 01-3.138-3.138 3.42 3.42 0 00-.806-1.946 3.42 3.42 0 010-4.438 3.42 3.42 0 00.806-1.946 3.42 3.42 0 013.138-3.138z\"><\/path><\/svg>\n      <\/div>\n      <div>\n        <div class=\"text-[10px] md:text-xs uppercase font-extrabold tracking-widest text-teal-500\">Live Score<\/div>\n        <div class=\"text-xl md:text-3xl font-black text-slate-100 flex items-baseline gap-1\">\n          <span id=\"score-correct\">0<\/span>\n          <span class=\"text-slate-500 text-sm md:text-lg font-bold\">\/ 25<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-3 bg-slate-950\/80 px-4 py-2 rounded-xl border border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-widest hidden sm:inline\">Progress<\/span>\n      <div class=\"w-24 md:w-32 bg-slate-800 h-2.5 rounded-full overflow-hidden\">\n        <div id=\"progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-teal-500 h-full w-0 transition-all duration-500 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-cyan-400\"><span id=\"score-answered\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <!-- Quiz Questions Container -->\n  <div class=\"space-y-6 relative\" id=\"mcq-container\">\n    \n    <!-- Q1 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">1.<\/span> \n        In the WHO classification of Pulmonary Hypertension (PH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) belongs to which group?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Group 1 is Pulmonary Arterial Hypertension (PAH), including idiopathic and heritable forms.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Group 1<\/button><button data-correct=\"false\" data-explanation=\"Group 2 is PH due to left heart disease (e.g., mitral valve disease or LV failure).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Group 2<\/button><button data-correct=\"false\" data-explanation=\"Group 3 is PH due to lung diseases and\/or hypoxia (e.g., COPD, ILD, sleep apnea).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Group 3<\/button><button data-correct=\"true\" data-explanation=\"Group 4 is designated specifically for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and other pulmonary artery obstructions. It is unique because it is potentially curable with pulmonary endarterectomy.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Group 4<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">2.<\/span> \n        What is the specific, FDA-approved reversal agent for the direct thrombin inhibitor Dabigatran?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Andexanet alfa is the reversal agent for Factor Xa inhibitors (like rivaroxaban and apixaban).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Andexanet alfa<\/button><button data-correct=\"false\" data-explanation=\"Protamine sulfate is the reversal agent for unfractionated heparin.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Protamine sulfate<\/button><button data-correct=\"true\" data-explanation=\"Idarucizumab is a monoclonal antibody fragment specifically designed to bind to dabigatran with high affinity, rapidly reversing its anticoagulant effect.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Idarucizumab<\/button><button data-correct=\"false\" data-explanation=\"Vitamin K is used to reverse the effects of Warfarin (a vitamin K antagonist).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Vitamin K (Phytonadione)<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">3.<\/span> \n        Which combination of electrocardiographic findings is the classic triad of Wolff-Parkinson-White (WPW) syndrome pattern?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"true\" data-explanation=\"WPW pattern is characterized by pre-excitation via the Bundle of Kent, leading to a short PR interval (&lt; 120 ms), a widened QRS complex (&gt; 120 ms), and a slurred upstroke of the QRS known as a delta wave.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Short PR interval &lt; 120 ms, wide QRS &gt; 120 ms, and a Delta wave<\/button><button data-correct=\"false\" data-explanation=\"A long PR interval (&gt; 200 ms) denotes first-degree AV block, which is the opposite of the pre-excitation seen in WPW.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Long PR interval &gt; 200 ms, narrow QRS &lt; 120 ms, and a Delta wave<\/button><button data-correct=\"false\" data-explanation=\"Osborn waves are seen in hypothermia, not WPW.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Short PR interval, wide QRS, and an Osborn wave<\/button><button data-correct=\"false\" data-explanation=\"Epsilon waves are characteristic of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Normal PR interval, narrow QRS, and an Epsilon wave<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">4.<\/span> \n        In the United States, what is historically the most common structural cause of sudden cardiac death in young competitive athletes?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Anomalous coronary artery origin is the second most common cause, but not the most common.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Anomalous origin of a coronary artery<\/button><button data-correct=\"true\" data-explanation=\"Hypertrophic Cardiomyopathy (HCM) is historically identified as the leading cause of sudden cardiac death in young competitive athletes in North America, often presenting as ventricular fibrillation during intense exertion.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Hypertrophic Cardiomyopathy (HCM)<\/button><button data-correct=\"false\" data-explanation=\"While ARVC is a prominent cause of SCD in athletes (especially in certain European regions like northern Italy), HCM is generally more prevalent in US data.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)<\/button><button data-correct=\"false\" data-explanation=\"Myocarditis can cause SCD, but it is less frequent than underlying genetic structural cardiomyopathies like HCM.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Viral myocarditis<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">5.<\/span> \n        Kussmaul sign is defined as a paradoxical rise (or failure to fall) of the Jugular Venous Pressure (JVP) during inspiration. It is classically associated with which condition?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Cardiac tamponade typically features pulsus paradoxus, but Kussmaul sign is classically absent.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Cardiac tamponade<\/button><button data-correct=\"true\" data-explanation=\"Kussmaul sign is typically seen in constrictive pericarditis, restrictive cardiomyopathy, or right ventricular infarction. The stiff or impaired right heart cannot accommodate the increased venous return during inspiration, causing blood to back up into the jugular veins.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Constrictive pericarditis<\/button><button data-correct=\"false\" data-explanation=\"Left ventricular failure does not directly cause an isolated Kussmaul sign unless it has progressed to severe right heart failure.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Isolated left ventricular failure<\/button><button data-correct=\"false\" data-explanation=\"Aortic regurgitation presents with peripheral signs like Corrigan pulse, not Kussmaul sign.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Severe aortic regurgitation<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">6.<\/span> \n        What is the normal anatomical orifice area of the adult mitral valve?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"This represents severe mitral stenosis (&lt; 1.5 cm2 is severe, &lt; 1.0 cm2 is very severe).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) 1.0 &#8211; 1.5 cm2<\/button><button data-correct=\"false\" data-explanation=\"This is the normal valve area for the aortic valve (typically 3-4 cm2).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) 2.5 &#8211; 3.5 cm2<\/button><button data-correct=\"true\" data-explanation=\"The normal orifice area of the adult mitral valve is between 4.0 and 6.0 cm2. Symptoms of mitral stenosis usually begin when the area falls below 2.0 cm2.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) 4.0 &#8211; 6.0 cm2<\/button><button data-correct=\"false\" data-explanation=\"This is too large for the normal mitral orifice area, approaching the size of the tricuspid valve.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) 7.0 &#8211; 9.0 cm2<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">7.<\/span> \n        Cilostazol is frequently used to treat claudication in peripheral artery disease (PAD). What is its primary pharmacological mechanism?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Clopidogrel and Prasugrel are P2Y12 inhibitors.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) P2Y12 ADP receptor antagonism<\/button><button data-correct=\"true\" data-explanation=\"Cilostazol is a phosphodiesterase-3 (PDE3) inhibitor. It increases intracellular cAMP, leading to both vasodilation of peripheral arteries and inhibition of platelet aggregation.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Phosphodiesterase-3 (PDE3) inhibition<\/button><button data-correct=\"false\" data-explanation=\"Sildenafil and Tadalafil are PDE5 inhibitors.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Phosphodiesterase-5 (PDE5) inhibition<\/button><button data-correct=\"false\" data-explanation=\"Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Irreversible Cyclooxygenase-1 (COX-1) inhibition<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">8.<\/span> \n        According to ACC\/AHA guidelines, adults aged 40-75 years with diabetes mellitus (without established atherosclerotic cardiovascular disease) should be prescribed:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Guidelines recommend routine statin therapy for this demographic regardless of baseline LDL, though risk enhancers may prompt high-intensity.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) No statin therapy unless LDL-C is &gt; 190 mg\/dL<\/button><button data-correct=\"true\" data-explanation=\"For primary prevention in adults aged 40-75 with diabetes, ACC\/AHA guidelines universally recommend at least moderate-intensity statin therapy, escalating to high-intensity based on a risk assessment.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Moderate-intensity statin therapy (or high-intensity based on risk)<\/button><button data-correct=\"false\" data-explanation=\"PCSK9 inhibitors are generally reserved for secondary prevention in very high-risk patients or familial hypercholesterolemia, not primary prevention first-line.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Upfront PCSK9 inhibitor therapy<\/button><button data-correct=\"false\" data-explanation=\"Low-intensity statins are rarely recommended as first-line therapy for diabetic patients in this age group due to their higher baseline risk.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Low-intensity statin therapy<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">9.<\/span> \n        The landmark PARTNER 3 and Evolut Low Risk trials definitively expanded the indication for Transcatheter Aortic Valve Replacement (TAVR) to which patient population?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"TAVR was initially approved for extreme\/prohibitive risk (PARTNER 1) and then high risk.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Prohibitive surgical risk patients<\/button><button data-correct=\"false\" data-explanation=\"Intermediate risk was proven in PARTNER 2.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Intermediate surgical risk patients<\/button><button data-correct=\"true\" data-explanation=\"The PARTNER 3 and Evolut Low Risk trials proved that TAVR is non-inferior (and in some metrics, superior) to surgical aortic valve replacement (SAVR) in patients at LOW surgical risk, radically changing standard practice.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Low surgical risk patients<\/button><button data-correct=\"false\" data-explanation=\"TAVR in bicuspid valves is still actively studied and sometimes used off-label, but these specific landmark trials focused on risk stratification in tricuspid aortic stenosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Patients with bicuspid aortic valve stenosis<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">10.<\/span> \n        Under the Modified Duke Criteria for infective endocarditis, which of the following is considered a MAJOR criterion?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"A fever &gt; 38.0 C is a minor criterion.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Fever &gt; 38.0 \u00b0C<\/button><button data-correct=\"false\" data-explanation=\"Osler nodes (immunologic phenomena) are a minor criterion.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Presence of Osler nodes<\/button><button data-correct=\"true\" data-explanation=\"Major criteria include two positive blood cultures with typical microorganisms (e.g., Viridans strep, S. aureus, HACEK) OR evidence of endocardial involvement (e.g., an oscillating vegetation on echocardiography).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) An oscillating vegetation on echocardiography<\/button><button data-correct=\"false\" data-explanation=\"Janeway lesions (vascular phenomena) are a minor criterion.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Presence of Janeway lesions<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">11.<\/span> \n        Guideline-Directed Medical Therapy (GDMT) for HFrEF is built upon &#8216;four pillars&#8217; of medications proven to reduce mortality. Which of the following correctly identifies these four classes?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Loop diuretics relieve congestion but do not have a proven robust mortality benefit in HFrEF.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) ACEi\/ARB, Beta-blocker, Loop Diuretic, Digoxin<\/button><button data-correct=\"true\" data-explanation=\"The four foundational pillars of HFrEF therapy proven to reduce morbidity and mortality are: 1) ARNI (or ACEi\/ARB), 2) Evidence-based Beta-blockers, 3) Mineralocorticoid Receptor Antagonists (MRA), and 4) SGLT2 inhibitors.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) ARNI\/ACEi\/ARB, Beta-blocker, MRA, SGLT2 inhibitor<\/button><button data-correct=\"false\" data-explanation=\"Ivabradine reduces hospitalizations in specific patients, and Hydralazine\/Nitrates are used in select populations, but they are not the universal 'four pillars'.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) ARNI, Beta-blocker, Ivabradine, Hydralazine\/Nitrates<\/button><button data-correct=\"false\" data-explanation=\"Calcium channel blockers (especially non-dihydropyridines) are generally contraindicated in HFrEF.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) ACEi\/ARB, Beta-blocker, Calcium Channel Blocker, MRA<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">12.<\/span> \n        Upon palpation of the carotid artery, a &#8216;pulsus parvus et tardus&#8217; (a weak and delayed pulse) is the classic physical examination finding for which valvular lesion?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Mitral stenosis affects LV filling but does not typically cause a delayed upstroke of the carotid pulse.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Mitral stenosis<\/button><button data-correct=\"false\" data-explanation=\"Aortic regurgitation produces a bounding, rapid upstroke and rapid collapse (Water-hammer or Corrigan pulse).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Aortic regurgitation<\/button><button data-correct=\"true\" data-explanation=\"Severe aortic stenosis obstructs left ventricular outflow, resulting in a classic carotid pulse that is weak\/small amplitude (parvus) and has a delayed upstroke (tardus).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Severe aortic stenosis<\/button><button data-correct=\"false\" data-explanation=\"HOCM typically produces a brisk initial upstroke followed by a mid-systolic dip (pulsus bisferiens or spike-and-dome pulse).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Hypertrophic obstructive cardiomyopathy (HOCM)<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">13.<\/span> \n        Dressler syndrome is a post-myocardial infarction pericarditis that typically presents weeks to months after the event. What is the first-line pharmacologic treatment?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Antibiotics are used for purulent\/bacterial pericarditis, not immune-mediated Dressler syndrome.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Broad-spectrum intravenous antibiotics<\/button><button data-correct=\"false\" data-explanation=\"Steroids are considered second-line for refractory cases because they can increase the risk of recurrent pericarditis and impair myocardial healing if used early post-MI.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) High-dose systemic corticosteroids<\/button><button data-correct=\"true\" data-explanation=\"Dressler syndrome is an autoimmune phenomenon. The first-line therapy is high-dose Aspirin (preferred post-MI over other NSAIDs) often combined with Colchicine to reduce inflammation and prevent recurrence.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) High-dose Aspirin and Colchicine<\/button><button data-correct=\"false\" data-explanation=\"Anticoagulation is generally contraindicated in acute pericarditis (unless strictly necessary) due to the risk of converting a dry effusion into a hemorrhagic tamponade.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Therapeutic anticoagulation with Warfarin<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">14.<\/span> \n        SGLT2 inhibitors (like Empagliflozin and Dapagliflozin) have shown dramatic benefits in heart failure. By what mechanism do they function in the kidney?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Loop diuretics (like furosemide) inhibit the Na-K-2Cl cotransporter in the Loop of Henle.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Inhibition of the Na-K-2Cl cotransporter in the Loop of Henle<\/button><button data-correct=\"true\" data-explanation=\"SGLT2 inhibitors block the Sodium-Glucose Co-Transporter 2 in the proximal convoluted tubule, preventing glucose and sodium reabsorption. This causes glucosuria, natriuresis, and osmotic diuresis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Inhibition of glucose and sodium reabsorption in the proximal tubule<\/button><button data-correct=\"false\" data-explanation=\"Aldosterone antagonists (MRAs like Spironolactone) work in the distal tubule and collecting duct.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Antagonism of aldosterone receptors in the distal tubule<\/button><button data-correct=\"false\" data-explanation=\"Thiazide diuretics inhibit the Na-Cl symporter in the distal convoluted tubule.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Inhibition of the Na-Cl symporter in the distal convoluted tubule<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">15.<\/span> \n        A patient with suspected Prinzmetal (variant) angina experiences episodes of resting chest pain with transient ST-segment elevation. Which class of medication should generally be AVOIDED as it may exacerbate symptoms?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Calcium channel blockers are a first-line therapy to prevent coronary vasospasm.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Calcium channel blockers<\/button><button data-correct=\"false\" data-explanation=\"Nitrates are highly effective at acutely relieving coronary vasospasm.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Long-acting nitrates<\/button><button data-correct=\"true\" data-explanation=\"Non-selective beta-blockers can block beta-2 mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed. This can precipitate or worsen severe coronary vasospasm in patients with Prinzmetal angina.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Non-selective Beta-blockers<\/button><button data-correct=\"false\" data-explanation=\"Statins are recommended to treat any underlying atherosclerosis and improve endothelial function.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) HMG-CoA reductase inhibitors (Statins)<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">16.<\/span> \n        The &#8216;Salvador Dali mustache&#8217; sign on an electrocardiogram is a classic descriptor for which of the following?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Acute pericarditis causes diffuse, concave ST elevation and PR depression.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) The diffuse ST elevation of acute pericarditis<\/button><button data-correct=\"false\" data-explanation=\"Anterior STEMI shows convex or tombstone ST elevation.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) The tombstone ST elevation of an anterior STEMI<\/button><button data-correct=\"true\" data-explanation=\"The 'Salvador Dali mustache' sign refers to the characteristic 'scooped' or sagging ST-segment depression seen in patients taking Digoxin (digoxin effect). It does not necessarily indicate toxicity, just the presence of the drug.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) The scooped ST-segment depression of Digoxin effect<\/button><button data-correct=\"false\" data-explanation=\"Wellens syndrome involves deeply inverted or biphasic T waves, not scooped ST segments.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) The biphasic T waves of Wellens syndrome<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">17.<\/span> \n        During a coronary angiogram, a Fractional Flow Reserve (FFR) measurement is taken across an intermediate lesion. Below what threshold value is the lesion considered hemodynamically significant, thereby justifying revascularization?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"0.90 is considered a negative result (the lesion is not causing significant ischemia).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) &lt; 0.95<\/button><button data-correct=\"false\" data-explanation=\"0.89 is the threshold for iFR (instantaneous wave-free ratio), not FFR.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) &lt; 0.89<\/button><button data-correct=\"true\" data-explanation=\"Based on trials like FAME and FAME 2, an FFR value of &lt;= 0.80 indicates that the coronary stenosis is hemodynamically significant (producing ischemia) and benefits from PCI compared to medical therapy alone.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) &lt;= 0.80<\/button><button data-correct=\"false\" data-explanation=\"Waiting for FFR to drop below 0.70 would miss many flow-limiting lesions.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) &lt;= 0.70<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">18.<\/span> \n        A patient presents to the ER with tearing chest pain. CT Angiography confirms a Stanford Type A aortic dissection. What is the immediate, definitive management strategy?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Medical management is the primary treatment for uncomplicated Stanford Type B dissections (descending aorta only).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Strict heart rate and blood pressure control in the ICU<\/button><button data-correct=\"true\" data-explanation=\"A Stanford Type A dissection involves the ascending aorta and carries a catastrophic risk of rupture, cardiac tamponade, and coronary\/carotid occlusion. It requires emergent surgical repair.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Emergent open surgical repair<\/button><button data-correct=\"false\" data-explanation=\"TEVAR is generally used for complicated Type B dissections, not Type A.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Endovascular stenting (TEVAR)<\/button><button data-correct=\"false\" data-explanation=\"Fibrinolytics would exacerbate the bleeding and likely be fatal.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Immediate administration of fibrinolytics<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">19.<\/span> \n        Brugada syndrome is a genetic channelopathy carrying a high risk of sudden cardiac death. It is most commonly associated with a loss-of-function mutation in which gene?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"KCNQ1 is associated with Long QT Syndrome Type 1 (LQT1).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) KCNQ1 (Potassium channel)<\/button><button data-correct=\"false\" data-explanation=\"RYR2 is associated with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) RYR2 (Ryanodine receptor)<\/button><button data-correct=\"true\" data-explanation=\"Brugada syndrome is most frequently (in ~30% of genotyped cases) associated with a mutation in the SCN5A gene, which encodes the alpha subunit of the cardiac sodium channel (Nav1.5).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) SCN5A (Sodium channel)<\/button><button data-correct=\"false\" data-explanation=\"MYBPC3 is the most common mutation in Hypertrophic Cardiomyopathy (HCM).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) MYBPC3 (Myosin-binding protein C)<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">20.<\/span> \n        A 25-year-old asymptomatic female is found to have a wide, fixed split S2 on cardiac auscultation. This finding is the hallmark of which congenital heart defect?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"true\" data-explanation=\"An Atrial Septal Defect (ASD) causes continuous left-to-right shunting, leading to volume overload of the right ventricle. This prolongs right ventricular ejection time, causing the pulmonary valve to close late, resulting in a wide, fixed split S2 that does not vary with respiration.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Atrial Septal Defect (ASD)<\/button><button data-correct=\"false\" data-explanation=\"A VSD produces a harsh, holosystolic murmur at the left lower sternal border, not a fixed split S2.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Ventricular Septal Defect (VSD)<\/button><button data-correct=\"false\" data-explanation=\"A PDA produces a continuous 'machinery-like' murmur.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Patent Ductus Arteriosus (PDA)<\/button><button data-correct=\"false\" data-explanation=\"Aortic stenosis causes a paradoxical (reversed) splitting of S2 due to delayed aortic valve closure.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Severe Aortic Stenosis<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">21.<\/span> \n        For a patient who receives a Drug-Eluting Stent (DES) during a percutaneous intervention for an Acute Coronary Syndrome (ACS), what is the standard guideline-recommended minimum duration of Dual Antiplatelet Therapy (DAPT)?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"1 month is standard for stable ischemic heart disease patients receiving a bare-metal stent (though guidelines are evolving, ACS requires longer).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) 1 month<\/button><button data-correct=\"false\" data-explanation=\"6 months is the standard minimum for stable ischemic heart disease (SIHD) receiving a DES.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) 6 months<\/button><button data-correct=\"true\" data-explanation=\"Regardless of the stent type, if a patient presents with an Acute Coronary Syndrome (STEMI\/NSTEMI), the ACC\/AHA guidelines strongly recommend DAPT for a minimum of 12 months to prevent stent thrombosis and recurrent ischemic events.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) 12 months<\/button><button data-correct=\"false\" data-explanation=\"While some high-risk patients may benefit from extended DAPT &gt; 12 months (PEGASUS-TIMI 54), it is not the minimum baseline recommendation for all.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) 24 months<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">22.<\/span> \n        Which of the following is typically the earliest electrocardiographic manifestation of hyperkalemia?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"QRS widening occurs later as potassium levels continue to rise (usually &gt; 6.5 mEq\/L).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Widening of the QRS complex<\/button><button data-correct=\"true\" data-explanation=\"The earliest ECG sign of hyperkalemia is tall, peaked, narrow-based, symmetric T waves. As K+ levels rise further, the PR interval prolongs, P waves flatten\/disappear, the QRS widens, and ultimately a sine wave pattern develops.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Tall, peaked, symmetric T waves<\/button><button data-correct=\"false\" data-explanation=\"Loss of the P wave is an intermediate-to-late sign of hyperkalemia.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Flattening or loss of the P wave<\/button><button data-correct=\"false\" data-explanation=\"A Sine wave pattern is a terminal, pre-arrest rhythm in severe hyperkalemia.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Sine wave pattern<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">23.<\/span> \n        Amiodarone is a highly effective Class III antiarrhythmic, but it has significant systemic toxicities. Patients on chronic therapy require regular monitoring of which three organ systems?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"Amiodarone does not typically cause bone marrow suppression or severe renal toxicity.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Kidneys, Bone Marrow, and Pancreas<\/button><button data-correct=\"true\" data-explanation=\"Amiodarone contains iodine and is highly lipophilic. Chronic use requires routine monitoring of the Lungs (pulmonary fibrosis), Thyroid (hyper\/hypothyroidism), and Liver (hepatotoxicity). Regular chest x-rays, TSH, and LFTs are mandatory.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Lungs, Thyroid, and Liver<\/button><button data-correct=\"false\" data-explanation=\"While it can cause optic neuritis\/corneal microdeposits, routine monitoring of CNS and Kidneys is not the primary triad.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Eyes, Kidneys, and Central Nervous System<\/button><button data-correct=\"false\" data-explanation=\"Spleen and intestines are not primarily affected by amiodarone toxicity.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Thyroid, Spleen, and Intestines<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">24.<\/span> \n        During transthoracic echocardiography, which specific finding is the most sensitive indicator of early hemodynamic compromise in a patient with a pericardial effusion?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"RV diastolic collapse is highly SPECIFIC for tamponade, but occurs later in the process.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Right ventricular early diastolic collapse<\/button><button data-correct=\"true\" data-explanation=\"Right Atrial (RA) late diastolic\/early systolic collapse is the most SENSITIVE and earliest echocardiographic sign of tamponade. Because the RA has the lowest resting pressure, it is the first chamber to collapse when intrapericardial pressure rises.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Right atrial late diastolic collapse<\/button><button data-correct=\"false\" data-explanation=\"LV diastolic collapse is a very late, pre-terminal sign of catastrophic tamponade.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Left ventricular diastolic collapse<\/button><button data-correct=\"false\" data-explanation=\"A swinging heart causes electrical alternans on the EKG, but RA collapse is the actual hemodynamic indicator of rising pressures.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) A &#8216;swinging heart&#8217; phenomenon<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">25.<\/span> \n        In the evaluation of stable ischemic heart disease, at what percentage of angiographic stenosis is the Left Main Coronary Artery (LMCA) generally considered hemodynamically significant, warranting revascularization?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\"><button data-correct=\"false\" data-explanation=\"30% is mild non-obstructive CAD.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) &gt; 30%<\/button><button data-correct=\"true\" data-explanation=\"Because the Left Main supplies the majority of the left ventricle, a stenosis of &gt; 50% is considered prognostically significant and is a Class I indication for revascularization (typically CABG, though PCI is an option in specific anatomies). For all other non-left main coronary arteries, the threshold is &gt; 70%.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) &gt; 50%<\/button><button data-correct=\"false\" data-explanation=\"70% is the threshold for significance in the other major epicardial vessels (LAD, LCx, RCA), but the Left Main threshold is lower.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) &gt; 70%<\/button><button data-correct=\"false\" data-explanation=\"Waiting for a 90% Left Main lesion is extremely dangerous and carries a very high mortality risk.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) &gt; 90%<\/button><\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  document.addEventListener('DOMContentLoaded', () => {\n    const cards = document.querySelectorAll('.mcq-card');\n    const scoreCorrectEl = document.getElementById('score-correct');\n    const scoreAnsweredEl = document.getElementById('score-answered');\n    const progressBar = document.getElementById('progress-bar');\n    \n    let correctCount = 0;\n    let answeredCount = 0;\n    const totalQuestions = cards.length;\n\n    cards.forEach(card => {\n      const buttons = card.querySelectorAll('.opt-btn');\n      const feedbackBox = card.querySelector('.feedback-box');\n\n      buttons.forEach(btn => {\n        btn.addEventListener('click', function() {\n          \n          \/\/ Prevent multiple answers on the same question\n          if (card.getAttribute('data-answered') === 'true') return;\n          card.setAttribute('data-answered', 'true');\n          \n          answeredCount++;\n          \n          \/\/ Use getAttribute to safely pull string values\n          const isCorrect = this.getAttribute('data-correct') === 'true';\n          const explanationText = this.getAttribute('data-explanation');\n\n          \/\/ Update Scoreboard UI\n          scoreAnsweredEl.innerText = answeredCount;\n          progressBar.style.width = `${(answeredCount \/ totalQuestions) * 100}%`;\n\n          if (isCorrect) {\n            correctCount++;\n            scoreCorrectEl.innerText = correctCount;\n          }\n\n          \/\/ Apply styling to buttons\n          buttons.forEach(b => {\n            b.disabled = true;\n            b.classList.remove('hover:bg-slate-800', 'cursor-pointer');\n            b.classList.add('opacity-50', 'cursor-not-allowed');\n            \n            \/\/ Highlight the correct answer no matter what\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'bg-slate-950', 'border-slate-700');\n              b.classList.add('opacity-100', 'bg-teal-950', 'border-teal-500', 'text-teal-300');\n              b.innerHTML += ' <span class=\"float-right text-teal-400 font-bold tracking-wider\">\u2713<\/span>';\n            }\n          });\n\n          \/\/ Highlight the clicked wrong answer\n          if (!isCorrect) {\n            this.classList.remove('opacity-50', 'bg-slate-950', 'border-slate-700');\n            this.classList.add('opacity-100', 'bg-rose-950', 'border-rose-500', 'text-rose-300');\n            this.innerHTML += ' <span class=\"float-right text-rose-400 font-bold tracking-wider\">\u2717<\/span>';\n          }\n\n          \/\/ Render the feedback box securely\n          feedbackBox.innerHTML = `\n            <div class=\"font-extrabold uppercase tracking-widest text-xs mb-1.5 ${isCorrect ? 'text-teal-400' : 'text-rose-400'}\">\n              ${isCorrect ? 'Correct!' : 'Incorrect'}\n            <\/div>\n            <p class=\"m-0 text-slate-300\">${explanationText}<\/p>\n          `;\n          \n          feedbackBox.classList.remove('hidden');\n          feedbackBox.classList.add(\n            'block', \n            isCorrect ? 'bg-teal-950\/30' : 'bg-rose-950\/30', \n            'border', \n            isCorrect ? 'border-teal-900\/50' : 'border-rose-900\/50'\n          );\n        });\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Advanced Clinical Series Cardiology MCQs: Part 8 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the WHO classification of Pulmonary Hypertension (PH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) belongs to which group? A) Group 1B) Group 2C) Group 3D) Group 4 2. What [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":67948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-67946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Advanced Clinical Series Cardiology MCQs: Part 8 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the WHO classification of Pulmonary Hypertension (PH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) belongs to which group? A) Group 1B) Group 2C) Group 3D) Group 4 2. What [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T00:42:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-23T09:55:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1263\" \/>\n\t<meta property=\"og:image:height\" content=\"706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"New Series of Interactive Cardiology MCQs 8\",\"datePublished\":\"2026-10-23T00:42:54+00:00\",\"dateModified\":\"2026-10-23T09:55:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/\"},\"wordCount\":1087,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/\",\"name\":\"New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg\",\"datePublished\":\"2026-10-23T00:42:54+00:00\",\"dateModified\":\"2026-10-23T09:55:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg\",\"width\":1263,\"height\":706},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Series of Interactive Cardiology MCQs 8\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/","og_locale":"en_US","og_type":"article","og_title":"New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders","og_description":"Advanced Clinical Series Cardiology MCQs: Part 8 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the WHO classification of Pulmonary Hypertension (PH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH) belongs to which group? A) Group 1B) Group 2C) Group 3D) Group 4 2. What [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-10-23T00:42:54+00:00","article_modified_time":"2026-10-23T09:55:22+00:00","og_image":[{"width":1263,"height":706,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"New Series of Interactive Cardiology MCQs 8","datePublished":"2026-10-23T00:42:54+00:00","dateModified":"2026-10-23T09:55:22+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/"},"wordCount":1087,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/","url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/","name":"New Series of Interactive Cardiology MCQs 8 - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg","datePublished":"2026-10-23T00:42:54+00:00","dateModified":"2026-10-23T09:55:22+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-8.jpg","width":1263,"height":706},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"New Series of Interactive Cardiology MCQs 8"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=67946"}],"version-history":[{"count":2,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67946\/revisions"}],"predecessor-version":[{"id":67971,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67946\/revisions\/67971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/67948"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=67946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=67946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=67946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}